Cutivue™, a health-tech project with global ambitions, opens an exclusive investment round

Innovation in healthcare is attracting strong interest in the investment community. Cutivue™, a mobile app leveraging AI for early detection of skin cancer, has launched its Pre-Seed round of €200,000. The structure: 10 qualified investors, each contributing €20,000, will obtain an individual 5% stake (50% in total).

With a differentiated approach — on-device AI, privacy by default, and global scalability — Cutivue™ positions itself as a strategic asset at the intersection of technology, digital health, and preventive care.

Key milestones over the next 12 months:

• Closed beta and first user data.

• Market launch in Europe and Latin America.

• Clinical pilots and teledermatology (beta).

• Clinical dossier and CE/FDA regulatory preparation.

“Cutivue™ is not just an app, it is a project with the ambition to become the global standard in dermatological risk screening,” says Pablo Gutiérrez-Ravé Villalón, founder.

The business model combines a B2C subscription (€4.99/month) with B2B API/SDK licensing for insurers and clinics, plus revenue from referral agreements.

With a minimum exit floor of €1 million and scenarios ranging from 2× to 5× ROI within 36 months, Cutivue presents itself as a unique investment opportunity in a fast-growing health-tech sector.

📩 Interested investors can access the Data Room under NDA upon request: info@luxonomy.net